HPR129 Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products
N Xander(Erasmus University Rotterdam), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Maximilian Salcher‐Konrad(London School of Economics and Political Science), Frederick W. Thielen(University Medical Center Freiburg), A Hendrickx(Intermutualist Agency)
Cited by 0
Related Papers
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3)
|Expert Review of Pharmacoeconomics & Outcomes Research|2016|138
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
|Milbank Quarterly|2020|87
Generating comparative evidence on new drugs and devices before approval
|The Lancet|2020|80